
Oestrogen-blocking treatments such as tamoxifen and aromatase inhibitors are commonly used for hormone-receptor-positive breast cancer because they lower or block oestrogen, helping prevent cancer recurrence. As oestrogen also plays a role in bone strength, metabolism, cardiovascular health, sexual comfort and emotional well-being, its reduction can lead to a range of treatment-related symptoms.
Supportive management helps women tolerate these therapies more comfortably by protecting bone and metabolic health, easing menopausal symptoms and maintaining quality of life throughout long-term treatment.
Oestrogen blockade refers to treatments that lower or block oestrogen in order to reduce the chance of breast cancer returning. Since hormone-receptor-positive breast cancers rely on oestrogen for growth, reducing this hormone is a key part of long-term therapy.
Oestrogen-blocking therapy is essential for reducing breast cancer recurrence, but the drop in oestrogen can cause symptoms that affect daily comfort, long-term health and treatment adherence. Mitigation helps manage these effects so women can continue therapy safely and comfortably.
Regular monitoring helps ensure that oestrogen-blocking treatments remain safe, effective and well tolerated. These assessments identify early changes in bone, metabolic and cardiovascular health so that supportive care can be introduced when needed.
A targeted medical approach helps reduce the physical impact of low oestrogen and supports adherence to breast cancer therapy. These strategies focus on bone health, symptom control and personalised adjustments to treatment when necessary.
Lifestyle changes play a key role in reducing the side effects of oestrogen-blocking therapy. Structured exercise, balanced nutrition and supportive routines help protect bone and metabolic health while improving overall quality of life.
Low oestrogen levels can affect sexual comfort, intimacy and emotional well-being. Supportive strategies help manage these changes so women can maintain confidence and quality of life throughout treatment.
Oestrogen plays a key role in bone density and metabolic stability. When levels fall during treatment, proactive monitoring and early intervention help prevent fractures, heart risks and metabolic complications.
Some women may develop symptoms or health concerns that warrant treatment adjustments or additional specialist input. Early review helps maintain comfort, safety and adherence throughout long-term therapy.
A structured mitigation plan helps women manage the side effects of oestrogen blockade more effectively. By combining medical treatments with lifestyle support, many women experience better comfort, health stability and quality of life throughout therapy.
Oestrogen-blocking therapy is a vital part of managing hormone-receptor-positive breast cancer, but the resulting drop in oestrogen can lead to symptoms that affect physical comfort, emotional well-being and long-term health. With the right mitigation plan, many of these effects can be managed effectively. Medical strategies such as bone-protective treatment, non-hormonal symptom support and carefully chosen medication adjustments work alongside lifestyle measures to protect bone health, stabilise metabolism, improve sexual comfort and support emotional balance. Regular monitoring ensures that changes are identified early and addressed promptly, helping women stay on their cancer therapy with greater confidence and ease.
If you are experiencing side effects from oestrogen-blocking treatment for breast cancer or would like a check for the side-effects of oestrogen lowering, schedule a consultation with The Metabolic Clinic to explore personalised strategies that support your bone, metabolic, emotional and sexual health throughout therapy.
Yes. Some symptoms settle as the body adapts, while others can be managed effectively with medical or lifestyle interventions.
Yes. Regular resistance and cardiovascular exercise can reduce fatigue, ease joint discomfort and support bone and metabolic health.
No. Side effects vary widely; some women experience only mild changes, while others benefit from additional supportive care.
In premenopausal women, ovarian suppression may temporarily halt ovarian function. Fertility planning should be discussed with oncology and reproductive specialists.
No. Joint pain is a common side effect of aromatase inhibitors and does not indicate poorer cancer control. It can often be managed successfully.
Yes. Non-hormonal moisturisers and lubricants are safe and effective. Low-dose local oestrogen may be an option if approved by an oncologist.
Non-hormonal treatments, lifestyle changes and medication review can help. A specialist can guide the safest and most effective options.
It may influence cholesterol, blood pressure or glucose control. Regular monitoring and lifestyle measures help protect cardiovascular health.
No. Weight gain can occur, but structured exercise, nutrition guidance and metabolic monitoring help maintain a healthy body composition.
Yes. Many women find that concentration, memory and clarity improve with sleep support, stress management and physical activity.
Switching may be considered if side effects significantly limit daily function. This decision should be guided by your oncologist.
Not always. They are recommended based on bone density results and individual risk of fracture.
Yes. Lubricants, moisturisers and pelvic floor therapy are effective. If symptoms persist, oncologist-approved local options may help.
Most women have regular reviews every 3–6 months, with periodic bone, metabolic and cardiovascular assessments depending on clinical needs.

MBBS (Hons), FRACP (Australia)
Dr. Dinesh lulus dengan predikat terpuji dari Monash University, Melbourne, pada 2009, dan menerima penghargaan Prince Henry's Prize in Surgery. Selama pelatihan endokrinologi di Melbourne, Dr. Dinesh memenangkan penghargaan registrar terbaik di Endocrine Society of Australia Clinical Weekend pada 2016, yang kemudian diikuti dengan keberhasilan beliau mendapatkan satu-satunya beasiswa fellowship Andrologi di Australia pada 2017. Sekembalinya ke Singapura, beliau menjabat sebagai pimpinan subspesialisasi untuk layanan adrenal, pituitari, dan tulang di Khoo Teck Puat Hospital serta mendirikan The Metabolic Clinic.
Sebagai pendidik yang berdedikasi, Dr. Dinesh menjabat sebagai Associate Programme Director untuk Endokrinologi di NHG, melatih calon-calon endokrinolog generasi berikutnya, dan menerima penghargaan NHG Teaching Award for Senior Doctors pada 2023. Sebagai seorang endokrinolog dengan kemahiran dalam bidang endokrinologi umum maupun subspesialisasi, beliau memiliki minat dalam bidang longevity (umur panjang) melalui peningkatan risiko kardiovaskular, metabolisme, kesehatan tulang, dan pencegahan penyusutan otot, yang bertujuan meningkatkan jumlah tahun hidup sehat seseorang.

Jika Anda merasa “tidak seperti biasanya” meskipun hasil tes normal, mengalami perubahan berat badan, kelelahan, atau gejala yang tidak dapat dijelaskan—saatnya untuk melihat lebih dalam.
Dapatkan kejelasan dan rencana yang disesuaikan dengan kondisi hormon dan kesehatan metabolik unik Anda.
Senin - Jumat
8:30 am to 5:30 pm
Sabtu
8:30 am – 12:30 pm
Minggu dan Libur Nasional: TUTUP
© 2026 The Metabolic Clinic. All Rights Reserved.